XML 69 R62.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Information - Schedule of Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Segment Reporting Information [Line Items]        
Revenue $ 46,435 $ 37,919 $ 131,498 $ 124,492
Operating expenses 79,067 88,875 260,210 280,459
Adjusted EBITDA [1] (14,300) (29,831) (63,926) (91,748) [2]
Net loss (32,097) (50,326) (125,878) (155,837)
Net loss attributable to noncontrolling interest 26 26 78 28
Net loss attributable to Adaptive Biotechnologies Corporation (32,071) (50,300) (125,800) (155,809)
Interest and other income, net (3,474) (4,282) (11,462) (10,918)
Interest expense [3] 2,939 3,652 8,628 10,788
Depreciation and amortization expense 4,591 5,763 14,808 16,839
Impairment of long-lived assets [4]     7,205  
Restructuring expense [4] 193   1,917  
Share-based compensation expense [2] 13,522 15,336 40,778 47,352
Operating Segments | MRD        
Segment Reporting Information [Line Items]        
Revenue 37,470 24,668 105,380 71,977
Operating expenses 52,538 55,977 170,785 170,946
Adjusted EBITDA [1] (6,120) (21,616) (34,668) (71,081) [2]
Net loss (15,068) (31,309) (65,405) (98,969)
Net loss attributable to Adaptive Biotechnologies Corporation (15,068) (31,309) (65,405) (98,969)
Depreciation and amortization expense 2,428 2,489 7,733 6,812
Impairment of long-lived assets [4]     2,819  
Restructuring expense [4] 167   1,195  
Share-based compensation expense [2] 6,353 7,204 18,990 21,076
Operating Segments | IM        
Segment Reporting Information [Line Items]        
Revenue 8,965 13,251 26,118 52,515
Operating expenses 20,689 26,400 70,663 88,753
Adjusted EBITDA [1] (5,212) (4,986) (19,172) (11,149) [2]
Net loss (11,724) (13,148) (44,545) (36,236)
Net loss attributable to Adaptive Biotechnologies Corporation (11,724) (13,148) (44,545) (36,236)
Depreciation and amortization expense 1,728 2,546 5,777 7,907
Impairment of long-lived assets [4]     4,386  
Restructuring expense [4] 26   722  
Share-based compensation expense [2] 4,758 5,616 14,488 17,180
Unallocated Corporate        
Segment Reporting Information [Line Items]        
Operating expenses 5,840 6,498 18,762 20,760
Adjusted EBITDA [1] (2,968) (3,229) (10,086) (9,518) [2]
Net loss (5,305) (5,869) (15,928) (20,632)
Net loss attributable to noncontrolling interest 26 26 78 28
Net loss attributable to Adaptive Biotechnologies Corporation (5,279) (5,843) (15,850) (20,604)
Interest and other income, net (3,474) (4,282) (11,462) (10,918)
Interest expense [3] 2,939 3,652 8,628 10,788
Depreciation and amortization expense 435 728 1,298 2,120
Share-based compensation expense [2] $ 2,411 $ 2,516 $ 7,300 $ 9,096
[1] Adjusted EBITDA is a non-GAAP financial measure. See “Management's Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation of how it is calculated and used by management.
[2] Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 11, Equity Incentive Plans for details on our share-based compensation expense.
[3] Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 8, Revenue Interest Purchase Agreement for details on the Purchase Agreement.
[4] Represents expenses recognized in conjunction with restructuring activities. See Note 12, Restructurings for details on our restructuring expenses.